Circulating tumor DNA methylation pattern (ctDNA methylation pattern)

Circulating tumor DNA methylation pattern recognition refers to the identification of tumor-derived DNA methylation signatures within circulating (cell-free) DNA, typically using noninvasive “liquid biopsy” approaches such as plasma sampling. These methylation profiles serve as highly sensitive and specific biomarkers for cancer diagnosis, tissue-of-origin detection, risk stratification, monitoring of minimal residual disease, and prediction of therapeutic response. Rather than being a discrete molecular target (such as a receptor, enzyme, or transcription factor), the methylation pattern itself is a complex, multi-locus epigenetic signature that reflects the tumor’s genetic and microenvironmental status. Recent computational approaches and targeted assays have enhanced the reliability and clinical applicability of ctDNA methylation patterns for early diagnosis, subtype classification, and prognosis across a range of cancer types. However, they are not themselves therapeutic targets, but rather powerful biomarkers for cancer management[1][3][4][5].\n\nClarification: \nThe query describes an analytic approach or biomarker (“Circulating tumor DNA methylation pattern recognition”), not an individual molecular target, gene, or protein. Thus, is_incorrect = true and is_target = false. There is no canonical protein/gene target or druggable molecule matching this name. The entry corresponds to a diagnostic method or analyte, not a conventional therapeutic target.

Other names

Circulating tumor DNA methylationctDNA methylationTumor DNA methylation in liquid biopsy